News Articles
Latest articles, insights, and updates from the blog.
Contact Ketamine Resource
Send corrections, partnership questions, or advertising inquiries.
Shared Serotonin Signal Found in Two Fast Antidepressants
New research finds a shared serotonin mechanism across two rapid-acting depression treatments, reshaping how clinicians and patients understand how these drugs work.
BPL-003 Reaches Phase III in Treatment-Resistant Depression
AtaiBeckley advances BPL-003 into Phase III for treatment-resistant depression. What this milestone means for patients and the TRD treatment landscape.
New Study: Ketamine Relieves Treatment-Resistant Depression
A new study reports ketamine relieves treatment-resistant depression and suicidal ideation. What the research means for patients exploring their options.
Ketamine for Depression: Why Your GP Stays Silent
Ketamine is producing real results for treatment-resistant depression, yet most GPs don't raise it. Here's what patients need to know about access and options.
Nevada Mental Health Expands Ketamine Treatment Access
Nevada Mental Health grows ketamine program through interventional psychiatry, signaling expanded access to innovative depression treatments.
New Study Shows IV Ketamine Beats Nasal Esketamine
Recent research reveals IV ketamine achieves higher remission rates than nasal esketamine for depression treatment. What this means for patients.
Psychiatrist Outlines Key Ketamine Patient Considerations
Dr. Benjamin Brody highlights critical patient considerations for ketamine treatment at major psychiatric conference. Key insights for treatment seekers.
Boston Clinics Spotlight Ketamine's Growing Role in Mental Health
Boston clinics are expanding ketamine therapy for mental health. What patients should know about access, cost, and what to expect from treatment.
Is Ketamine the Future of Mental Health Treatment?
A local news segment spotlights ketamine therapy's growing role in mental health. Here's what the coverage gets right — and what patients should know.
Psych Deprescribing Debate: What It Means for Ketamine
HHS targets psychiatric overprescribing. Experts say stop what's not working—and replace it with evidence-based alternatives. Here's how ketamine fits in.
CBT After Esketamine Cuts Relapse Risk, Trial Finds
The CBT-ENDURE trial found that pairing esketamine with 16 weeks of CBT reduced suicidal ideation and depression severity better than esketamine alone.
Schizophrenia Survey Reveals Gaps That Echo Across Psychiatry
A new SPAN survey exposes persistent care gaps in schizophrenia treatment. Here's why those findings matter across the broader psychiatric landscape.
Faster TRD Remission: Why Measurement-Based Care Matters
New clinical guidance on TRD emphasizes fast dose adjustments and symptom tracking—here's what it means for patients considering ketamine therapy.